All the events here are relevant to people working in dementia research. If you would like to add your own you can submit an event
![Loading Events](https://www.dementiaresearcher.nihr.ac.uk/wp-content/plugins/the-events-calendar/src/resources/images/tribe-loading.gif)
- This event has passed.
LinkAGE Webinar – CRISPR
21/02/2023 @ 5:00 pm - 6:00 pm
![APOE4 - DEMENTIA RESEARCHER](https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2021/05/APOE4.png)
Welcome to the second of our new series of expert webinars. The LinkAGE (Linking Academia and Genomics Education) series will aim to provide expert seminars on exciting ‘bench-to-bedside’ projects that are likely to impact on clinical practice in the not-too-distant future.
Our second webinar and Q&A session in the series will be broadcast live on Tuesday 21 February at 5pm and will provide an introduction to CRISPR and the history of gene editing and is presented by cellular therapeutics expert Dr James Patterson. The webinar and Q&A will cover:
- an introduction to CRISPR and the history of gene editing;
- Cas9 as the de facto gene editing system;
- alternate Cas enzymes and their potential use cases;
- functionalising Cas enzymes for non-natural function;
- an overview of the CRISPR therapeutics landscape; and
- a discussion of key challenges facing CRISPR’s use in the clinic and its future outlook.
Who is the LinkAGE expert webinar series aimed at?
This webinar series is aimed at researchers, clinicians and other healthcare professionals who already have a strong understanding of fundamental genomics concepts. If you are just starting your learning journey, or need a quick refresher, we encourage you to check out our genetics and genomics learning centre.
Meet the speaker
James Patterson, MB/PhD, currently works in Cambridge, UK on his start-up Xap Therapeutics. James studied medicine at Cambridge, where he spent most summers working on a diverse set of projects, from worms to cancer stem cells. He graduated with a degree in medicine/biochemistry before moving to the Francis Crick Institute to complete his MB/PhD on fission yeast cell size control with the Nobel prize winner Sir Paul Nurse. Separate to his academic work, James developed and built an IP focused biotech company – Auxolytic – which demonstrated proof of concept of a CRISPR-engineered cell therapy safety switch. In 2018, James founded Xap Therapeutics, a biotech company developing a CRISPR engineered, iPSC-derived delivery vehicle for complex therapeutics.
Register your interest
If you would like to join us on the 21st February, please complete the registration form today.